| Revenue growth | 16.6% YoY in FY26; 16.7% in Q4. |
|---|---|
| Margins | EBITDA margin improved 80bps to 19.4% in FY26. |
| Order book | Robust ARV order book; healthy non-ARV pipeline. |
| Demand visibility | Strong across women's health, cardiac, CNS, and international markets. |
| Management confidence | High; citing 5-year strategy and AI adoption outcomes. |
Growth
FY26 revenue hit ₹9,204cr (+16.6%); Domestic grew 10%; International surged 22.2%. Adjusted PAT rose to ₹1,008cr.
Outlook
FY27 guidance: low to mid-teen revenue growth; EBITDA margin expansion of 75-100bps; Capex of ₹400-425cr.
Risks
Restructuring and high attrition in Zuventus portfolio; rising raw material and freight costs due to geopolitical conflicts.
Earnings Call filed with NSE, NSE: EMCURE. Summary written with AI assistance from the document.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,905.90
- Market cap
- ₹36,157 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 35.8×Sector 47.4×
- Promoter holding
- 77.83%-0.04% QoQ
- FII holding
- 4.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure Pharmaceuticals Credit Rating
Emcure Pharmaceuticals received a credit rating reaffirmation from CARE Ratings for its existing bank facilities. The company maintains its stable outlook and financial profile.
Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 as part of its Annual Report.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals has issued a notice for its 45th Annual General Meeting to be held on September 21, 2026. The meeting will address financial statements, dividends, and directorship appointments.